- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01222884
A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D
November 2, 2015 updated by: Pharmacosmos A/S
A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With Intravenous Iron Sucrose in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)
The purpose of this study is to compare the efficacy and safety of intravenous iron isomaltoside 1000 with intravenous iron sucrose in patients suffering from Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
351
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Mumbai, India
- Jatin Kothari
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Subjects with a diagnosis of CKD-5D, in dialysis therapy for at least 90 days prior to inclusion, will be included if they meet all of the following criteria:
- Men or women, aged 18 years or greater.
- Subjects diagnosed with CKD-5D and in haemodialysis therapy for at least 90 days.
- Life expectancy beyond 12 months by Principal Investigator's judgement.
- Willingness and ability to participate after Informed Consent.
- Hb concentrations between 9.5 g/dL and 12.5 g/dL (both values included) both at Screening Visit 1a and at Screening Visit 1b (screening Visit 1a and Visit 1b must be separated by at least 1 week).
- Serum ferritin < 800 ng/mL.
- Transferrin Saturation < 35%.
- Subjects receiving ESA treatment with dose stable for the previous 4 weeks prior to screening (with only 1 missed dose to be allowed. Dose to be kept stable during the study period).
- Subjects receiving no IV iron or an average of no more than 100 mg/week for the previous 4 weeks (with only 1 missed dose to be allowed).
Exclusion Criteria:
- Anaemia caused primarily by factors other than renal related anaemia.
- Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and haemosiderosis).
- Patients currently undergoing treatment with immunosuppresives (low dose steroids are allowed during the study conduct for dosages no more than 10 mg prednisolone/day or equivalent. If possible the dosage should be kept constant through the study).
- Difference of Hb ≥ 1.0 g/dL between screening (Visits 1a and 1b).
- Patients with a history of multiple allergies.
- Decompensated liver cirrhosis or active hepatitis [Alanine Aminotransferase (ALT) > 3 times normal] or history of Hepatitis B or C.
- Active acute or chronic infections (assessed by clinical judgement), supplied with White Blood Cells (WBC) and C - reactive protein (CRP).
- Rheumatoid arthritis with symptoms or signs of active joint inflammation.
- Pregnancy or nursing. [To avoid pregnancy, women have to be postmenopausal (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: Contraceptive pills, Intrauterine Devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches]
- Blood transfusion within the previous 12 weeks.
- Planned elective surgery in the next 8 weeks.
- Participation in any other clinical trial within the past 30 days, or if longer, where the study drug has not passed five half-lives prior to screening.
- Untreated Vitamin B12 or folate deficiency.
- Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study. Examples include Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Iron isomaltoside 1000
Iron isomaltoside 1000 (Monofer)administered as 500 mg intravenous single bolus injections OR administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
|
Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
|
ACTIVE_COMPARATOR: Iron sucrose
Iron sucrose administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
|
Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ability to Maintain Hemoglobin Level
Time Frame: Baseline to 6 weeks
|
The primary outcome measure was the proportion of subjects who were able to maintain haemoglobin between 9.5 and 12.5 g/dL (both values included) at week 6.
Haemoglobin was measured by a blood sample at the different visits.
All blood samples were taken before the dialysis from the dialysis catheter.
Intravenous iron was administered during dialysis, at least 30 min after the start and at least 1 h before the end of dialysis.
|
Baseline to 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Hemoglobin Concentration
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2011
Primary Completion (ACTUAL)
October 1, 2013
Study Completion (ACTUAL)
December 1, 2013
Study Registration Dates
First Submitted
October 15, 2010
First Submitted That Met QC Criteria
October 15, 2010
First Posted (ESTIMATE)
October 18, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
December 2, 2015
Last Update Submitted That Met QC Criteria
November 2, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P-Monofer-CKD-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease Stage 5 (Dialysis Dependent)
-
Heinrich-Heine University, DuesseldorfRecruitingVaccine Response Impaired | Chronic Kidney Disease Stage 5 on Dialysis | Chronic Kidney Disease Stage 5 With TransplantGermany
-
VA Office of Research and DevelopmentRecruitingChronic Kidney Disease (CKD) Stage 5 | Kidney Dysfunction Requiring Dialysis (KDRD) | Dialysis DependencyUnited States
-
University Hospital of FerraraUniversità degli Studi di FerraraRecruitingChronic Kidney Disease Stage 5 on DialysisItaly
-
Coordinación de Investigación en Salud, MexicoUnknownChronic Kidney Disease Stage 5 | Peritoneal Dialysis ComplicationMexico
-
National University of SingaporeUnknownHemodialysis | Peritoneal Dialysis | Stage 5 Chronic Kidney DiseaseSingapore
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
Zydus Lifesciences LimitedCompletedChronic Kidney Disease Stage 5 on DialysisIndia
-
Policlinico Casilino ASL RMBIRCCS San RaffaeleUnknownHypercholesterolemia | CKD Stage 5 | Chronic Kidney Disease Requiring Chronic DialysisItaly
-
Universitas PadjadjaranCompletedChronic Kidney Disease Stage 5 on DialysisIndonesia
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...CompletedChronic Kidney Diseases | Blood Pressure | Chronic Kidney Disease Stage 5 | End Stage Renal Disease on Dialysis (Diagnosis)United States
Clinical Trials on Monofer
-
Pharmacosmos A/SCompleted
-
University of GlasgowPharmacosmos A/S; British Heart Foundation; NHS Greater Glasgow and ClydeCompletedChronic Heart Failure | Iron Deficiency | Left Ventricular Systolic DysfunctionUnited Kingdom
-
Pharmacosmos A/SCompletedAnemia, Iron-Deficiency | Chronic Kidney DiseaseDenmark
-
Pharmacosmos A/SCompleted
-
Pharmacosmos A/SMax NeemanCompleted
-
Qianfoshan HospitalRecruitingIron Deficiency Anemia of Pregnancy | Iron Storage DiseaseChina
-
Ministry of Health, MalaysiaUniversity of MalayaUnknown
-
Pharmacosmos A/SClinSmartCompleted
-
Yonsei UniversityNot yet recruitingKidney Failure, ChronicKorea, Republic of
-
Pharmacosmos A/SRecruitingIron Deficiency, Anaemia in ChildrenUnited States